Prostate Cancer & PSA Tumors News Articles

Prostate Cancer News

PROSTATE CANCER ADVISOR

Prostate Cancer News

Earlier Cabazitaxel Use in mCRPC Possibly Beneficial

Phase 2 trial results suggests abiraterone used in combination in cabazitaxel in men with chemotherapy-naïve metastatic castration-resistant prostate cancer might prolong radiographic progression-free survival compared with abiraterone alone.

Longer Survival Seen With Sipuleucel-T Use in mCRPC

In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.
Bone Metastases

Optimal Drug Sequencing for mCRPC Reported

For men with newly diagnosed metastatic castration-resistant prostate cancer, starting with abiraterone plus prednisone followed by enzalutamide upon PSA progression significantly prolongs time to second PSA progression compared with the opposite sequence, a study found.